Immunological considerations for COVID-19 vaccine strategies

Mangalakumari Jeyanathan; Sam Afkhami; Fiona Smaill; Matthew S Miller; Brian D Lichty; Zhou Xing

doi:10.1038/s41577-020-00434-6

Immunological considerations for COVID-19 vaccine strategies

Nat Rev Immunol. 2020 Oct;20(10):615-632. doi: 10.1038/s41577-020-00434-6. Epub 2020 Sep 4.

Authors

Mangalakumari Jeyanathan^#^{1

2

3}, Sam Afkhami^#^{1

2

3}, Fiona Smaill^{2

3}, Matthew S Miller^{1

3

4}, Brian D Lichty^{5

6}, Zhou Xing^{7

8

9}

Affiliations

¹ McMaster Immunology Research Centre, McMaster University, Hamilton, ON, Canada.
² Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada.
³ Michael G. DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, ON, Canada.
⁴ Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada.
⁵ McMaster Immunology Research Centre, McMaster University, Hamilton, ON, Canada. blichty@mac.com.
⁶ Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada. blichty@mac.com.
⁷ McMaster Immunology Research Centre, McMaster University, Hamilton, ON, Canada. xingz@mcmaster.ca.
⁸ Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada. xingz@mcmaster.ca.
⁹ Michael G. DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, ON, Canada. xingz@mcmaster.ca.

^# Contributed equally.

Abstract

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the most formidable challenge to humanity in a century. It is widely believed that prepandemic normalcy will never return until a safe and effective vaccine strategy becomes available and a global vaccination programme is implemented successfully. Here, we discuss the immunological principles that need to be taken into consideration in the development of COVID-19 vaccine strategies. On the basis of these principles, we examine the current COVID-19 vaccine candidates, their strengths and potential shortfalls, and make inferences about their chances of success. Finally, we discuss the scientific and practical challenges that will be faced in the process of developing a successful vaccine and the ways in which COVID-19 vaccine strategies may evolve over the next few years.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Antibodies, Viral / biosynthesis*
Betacoronavirus / drug effects
Betacoronavirus / immunology*
Betacoronavirus / pathogenicity
COVID-19
COVID-19 Vaccines
Clinical Trials as Topic
Coronavirus Infections / epidemiology
Coronavirus Infections / immunology
Coronavirus Infections / prevention & control*
Coronavirus Infections / virology
Genetic Vectors / chemistry
Genetic Vectors / immunology
Humans
Immunity, Herd / drug effects
Immunity, Innate / drug effects
Immunization Schedule
Immunogenicity, Vaccine
Pandemics / prevention & control*
Patient Safety
Pneumonia, Viral / epidemiology
Pneumonia, Viral / immunology
Pneumonia, Viral / prevention & control*
Pneumonia, Viral / virology
SARS-CoV-2
Severe Acute Respiratory Syndrome / epidemiology*
Severe Acute Respiratory Syndrome / immunology
Severe Acute Respiratory Syndrome / prevention & control*
Severe Acute Respiratory Syndrome / virology
Vaccines, Attenuated
Vaccines, DNA
Vaccines, Subunit
Vaccines, Virus-Like Particle
Viral Vaccines / administration & dosage
Viral Vaccines / biosynthesis
Viral Vaccines / immunology*

Substances

Antibodies, Viral
COVID-19 Vaccines
Vaccines, Attenuated
Vaccines, DNA
Vaccines, Subunit
Vaccines, Virus-Like Particle
Viral Vaccines